Introduction & Objective: This study aimed to assess the real-world impact of sema OW vs SGLT2i on HbA1c, weight and HCRU outcomes among patients (pts) with T2D in the US.

Methods: This observational study of adults with uncontrolled T2D (HbA1c ≥7%) initiating sema OW or SGLT2i (Jan 2018—Feb 2022; first prescription = index) used data from IQVIA PharMetrics® Plus and Ambulatory Electronic Medical Records databases. Changes in HbA1c, weight, BMI and all-cause medical HCRU outcomes after 1 year were compared among inverse probability of treatment weighting (IPTW) adjusted cohorts.

Results: Post-IPTW (sema OW: n=416; SGLT2i: n=1093) a significantly higher proportion of pts in the sema OW cohort had combined reductions in HbA1c/weight outcomes vs SGLT2i (Figure). The sema OW cohort had significantly greater mean decreases in HbA1c (-1.6 vs -1.2%, p<0.0001), weight (-4.4 vs -3.4 kg, p<0.0001) and BMI (-1.5 vs -1.1 kg/m2, p=0.013) vs SGLT2i. Over 1-yr follow-up, all-cause HCRU was similar between both cohorts (≥1 hospitalization: 6.0 vs 5.7%, p=0.8190; ≥1 ER visit: 15.2 vs 17.6%, p=0.2658; ≥1 physician office visit: 99.7 vs 99.1%, p=0.2134).

Conclusion: Sema OW was associated with greater improvements in HbA1c and weight vs SGLT2i, but with similar HCRU after 1 year.

graphic
View largeDownload slide
Disclosure

J. Amamoo: None. R.P. Doshi: None. J. Noone: Employee; Novo Nordisk. L. Xie: None. C.L. Gamble: Employee; Novo Nordisk. M. Guevarra: Stock/Shareholder; Novo Nordisk. V. Divino: Employee; IQVIA Inc. J. Chen: None. A.A. King: Speaker's Bureau; Abbott, MannKind Corporation, Novo Nordisk. Advisory Panel; Novo Nordisk. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Lilly Diabetes. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Dexcom, Inc. Speaker's Bureau; Astellas Pharma Inc.

Funding

Novo Nordisk

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.